As someone who's been treated successfully for ALL I'm certainly interested in this, as no one knows with certainty that it won't return. They're not dealing with the same for of ALL that I had, but once thing I've learned is that off label use of these drugs is common, they don't try drugs on all forms of the disease it could possibly work with.
I had stem cells about 4.5 years ago and remain on oral chemo, which might be used for the rest of my life. My odds are good without it, but much better with it, so it continues, and I continue to deal with its side effects, which aren't pleasant.
I can't say I'd get off the chemo if IMGN's drug is approved, but I certainly would like to know of alternatives if I did come out of remission.
As an investor in IMGN since it came public, I would hope this product is one that IMGN maintains substantial ownership in, I know Jazz has opt in rights and expect them to use them at one of their option points as long as trial result's continue to impress.
I also hope IMGN853 is ROW partnered sometime soon. I believe results prove it should be approved after a properly structured trial, but it certainly isn't worth what it might have been worth had the Phase 3 data been worthy of approval without an additional trial being needed.
Gary
I had stem cells about 4.5 years ago and remain on oral chemo, which might be used for the rest of my life. My odds are good without it, but much better with it, so it continues, and I continue to deal with its side effects, which aren't pleasant.
I can't say I'd get off the chemo if IMGN's drug is approved, but I certainly would like to know of alternatives if I did come out of remission.
As an investor in IMGN since it came public, I would hope this product is one that IMGN maintains substantial ownership in, I know Jazz has opt in rights and expect them to use them at one of their option points as long as trial result's continue to impress.
I also hope IMGN853 is ROW partnered sometime soon. I believe results prove it should be approved after a properly structured trial, but it certainly isn't worth what it might have been worth had the Phase 3 data been worthy of approval without an additional trial being needed.
Gary
